Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Eli Lilly VIVID-1 Study

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderatly to Severly Active Crohn’s Disease

Crohn’s Disease
AGE: 18- 80 years old
TYPE: Investigational Drug Study
CONDITION: Crohn’s Disease

Learn More About This Research Study

Please call Nancy Furey, study coordinator, at 216-844-7314 for more information or complete the online form below.

Purpose of the Study

The purpose of the study is to see if the study drug Mirikizumab is safe and effective in participants with moderately to severely active Crohn’s Disease.

Who Can Participate

Participants 18 years and older diagnosed with moderate to severe Crohn’s Disease three months prior to starting this study may be eligible to participate.


Request More Information

To learn more about this study, please fill out the form below to request more information.

I'm not a robot